Astra Zeneca (Israel) Ltd

Aromatase Inhibitor. Anastrozole 1 mg.
TABS: 28. Adults and elderly: 1 tab. dly.
Advanced breast cancer in post-menopaus.
women. Adjuv. tmt of
postmenopaus. women with hormone
receptor-positive early invasive breast
cancer. Adjuv. tmt. early breast cancer in
hormone receptor +tive postmenopaus.
women who have received 2-3 yrs.
adjunct. tamoxifen.
C/I: Severe ren. impair., mod. or severe
hepat. dis., pregn., lact.

Antiplatelet Agent. Ticagrelor 60 mg, 90 mg.
F.C. TABS: 56. Pts. taking Ticagrelor should also take ASA dly., unless specific. contraind.
Follow. an init. dose of ASA, Ticagrelor should be used with a mainten. dose of ASA of 75-150 mg.
Acute coron. syndr.: Ticagrelor tmt. should be initi. with a single 180 mg load. dose (2 tabs. of 90 mg) and then contin. at 90 mg ×2/d.
Tmt. with Ticagrelor 90 mg ×2/d is recomm. for up to 12 mnths. in ACS pts. unless discont. is clinic. indic.
Ticagrelor 60 mg ×2/d dly. is the recomm. dose when an extend. tmt. is requir. for pts. with a hist. of MI of at least 1 year and a high risk of an atherothrombot. event. Tmt. may be started without interrupt. as contin. ther. after the init. 1 -year tmt. with Ticagrelor 90 mg or other adenosine diphosphate (ADP) recept. inhib. ther. in ACS pts. with a high risk of an atherothrombot. event. Tmt. can also be init. up to 2 yrs. from the MI, or within 1 year after stop. prev. ADP recept. inhibit. tmt.
In pts. with ACS, premat. discont. with any antiplat. ther., includ. Ticagrelor, could result in an incr. risk of cardiovasc. death, or MI due to the pt’s. underlying dis. Therefore, premature discont. of tmt. should be avoided. See lit.
Indic. co-admin. with ASA, is for the preven.  of atherothrombot. events in adult pts. with - acute coron. syndr. (ACS) or - a hist. of MI and a high risk of develop. an atherothrombot.
Limitations of use: 90 mg ×2/d during the 1^st year after an ACS event follow. by 60 mg ×2/d for addit. 2 yrs.
C/I: Hypersens. Active pathology. bleed. History of intracran. haemorr. Severe hep. impair. Co-admin. with strong CYP3A4 inhib. (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir).

Corticosteroid. Budesonide 0.5 mg.
INHAL. SUSP: 20 (single dose). Initial: 1-2
mg, total dly dose. Child: 6 mths and
older: 0.25-0.5 mg total dly dose. Pts
on oral gluco-corticosteroids: Higher
start. dose: 1 mg total dly dose. Maint:
Titrate to lowest effect. dose: Range:
0.5-4 mg total dly dose. Severe cases:
May incr. further. Child 6 mths and
older: 0.25-2 mg total dly dose. Admin.
1-2 x dly.
Bronch. asth. when other ther. unsuit. or
insuffic.

Corticosteroid. Budesonide 1 mg.
INHAL. SUSP: 20 (single dose). Initial: 1-2
mg, total dly dose. Child: 6 mths and
older: 0.25-0.5 mg total dly dose. Pts
on oral gluco-corticosteroids: Higher
start. dose: 1 mg total dly dose. Maint:
Titrate to lowest effect. dose: Range:
0.5-4 mg total dly dose. Severe cases:
May incr. further. Child 6 mths and
older: 0.25-2 mg total dly dose. Admin.
1-2 x dly.
Bronch. asth. when other ther. unsuit. or
insuffic.

Corticosteroid. Budesonide 100 mcg/dose , 200 mcg/dose.
TURBUHALER: 200 inhals. x 100 μg;
100 inhals. x 200 μg. Severe asth. or
while reduc. or withdraw oral
corticoster: 200-1600 μg dly. div. into
2-4 admins. Maint: Lowest dose that
keeps pt. sympt. free. Admin. 2 x dly.
Morn and even. usually suffic. Child: 6
yrs. and over: 200-800 μg. dly. in 2
admins.
See lit.
Bronch. asth.

Incretin Mimetic. Exenatide 2 mg.
PWDR. IN VIALS + SOLVENT
for susp. for inj. 3 x 4 single-dose kits
recommen. dose is 2 mg once weekly,
for self administ. by the pts.
type 2 diab. mellitus in combin.with
Metformin, Sulphonylurea, Metformin and
sulphonylurea in adults who have not
achieved adequate glycaemic control on
maximally tolerated doses of these oral
therapies.
C/I: Hypersens.to the active subst. or to
any of the excipients